OncoMatch/Clinical Trials/NCT06397222
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Is NCT06397222 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sin-Bev-SIRT for hepatocellular carcinoma non-resectable.
Treatment: Sin-Bev-SIRT — This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C, CNLC II, CNLC III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hepatic arterial infusion chemotherapy
Patients who previously received hepatic arterial infusion chemotherapy (HAIC)
Cannot have received: transarterial chemoembolization
transarterial chemoembolization (TACE)
Cannot have received: transarterial embolization
transarterial embolization (TAE)
Cannot have received: radiation therapy
radiotherapy
Cannot have received: systemic therapy
systemic therapy for HCC
Lab requirements
Blood counts
Peripheral blood white blood cell count ≥3×10^9/L and platelet count ≥50×10^9/L
Liver function
Child-Pugh score 5-7; no hepatic dysfunction such as ascites, esophagogastric varices, hepatic encephalopathy; no evidence of portal hypertension with high risk of bleeding; prolonged prothrombin time >4 seconds excluded
Child-Pugh score 5-7. Hepatic dysfunction, such as ascites, esophagogastric varices, hepatic encephalopathy [excluded]. Evidence of portal hypertension with high risk of bleeding [excluded]. Peripheral blood white blood cell count <3×10^9/L and platelet count <50×10^9/L [excluded]. Prolonged prothrombin time >4 seconds [excluded]. Severe organ (heart, lung, kidney) dysfunction [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify